PMID- 3518726
OWN - NLM
STAT- MEDLINE
DCOM- 19860528
LR  - 20131121
IS  - 0004-4172 (Print)
IS  - 0004-4172 (Linking)
VI  - 36
IP  - 2A
DP  - 1986 Feb
TI  - The efficacy of ibopamine in long-term treatment of dilated cardiomyopathy. A 
      clinical and instrumental evaluation.
PG  - 390-4
AB  - The aim of this study was to investigate whether long-term treatment with 
      ibopamine (SB-7505), the 3,4-diisobutyryl ester of N-methyldopamine, in patients 
      with severe symptomatic congestive cardiomyopathy is associated with an 
      improvement in cardiovascular conditions. The investigation was carried out in 18 
      outpatients with idiopathic or post-ischemic dilated cardiomyopathy and chronic 
      severe heart failure (NYHA (New York Heart Association) Class III-IV). Patients 
      were randomly assigned to a protocol in which either digitalis and diuretics (8 
      patients, Group 2) or the same treatment plus ibopamine (10 patients, Group 1) 
      were given. There were no significant differences between the two groups in age, 
      weight, height, functional class and duration of symptoms. The results obtained 
      showed that cardiovascular conditions worsened dramatically in the group of 
      controls during the 10-week period, irrespective of the treatment with digitalis 
      and diuretics. Some of the parameters deteriorated significantly (p less than 
      0.05 or less than 0.01) such as systolic and diastolic left ventricular 
      diameters, fractional shortening, end-systolic stress and pressure/diameter 
      ratio, and other parameters showed a tendency to become worse (exercise time, 
      cardiothoracic ratio). On the contrary, in patients of group 1, ibopamine in 
      association with digitalis and diuretics appeared to preserve left ventricle 
      function from a progressive worsening. None of the parameters deteriorated with 
      ibopamine by contrast with a sharp decrease in the control group. Some of the 
      parameters (fractional shortening, pressure/diameter ratio, exercise time) showed 
      a tendency to improve although not significantly. The data suggest than 10 weeks 
      treatment with ibopamine may prevent any deterioration or even produce a mild 
      improvement in patients with very severe congestive heart failure.
FAU - Benassi, A
AU  - Benassi A
FAU - Modena, M G
AU  - Modena MG
FAU - Mattioli, G
AU  - Mattioli G
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Germany
TA  - Arzneimittelforschung
JT  - Arzneimittel-Forschung
JID - 0372660
RN  - 0 (Cardiotonic Agents)
RN  - 8ZCA2I2L11 (ibopamine)
RN  - R7339QLN1C (Deoxyepinephrine)
RN  - VTD58H1Z2X (Dopamine)
SB  - IM
MH  - Adult
MH  - Cardiomyopathy, Dilated/*drug therapy/physiopathology
MH  - Cardiotonic Agents/adverse effects/*therapeutic use
MH  - Chronic Disease
MH  - Clinical Trials as Topic
MH  - Deoxyepinephrine/adverse effects/*analogs & derivatives/therapeutic use
MH  - Dopamine/*analogs & derivatives
MH  - Echocardiography
MH  - Exercise Test
MH  - Female
MH  - Humans
MH  - Male
MH  - Random Allocation
EDAT- 1986/02/01 00:00
MHDA- 1986/02/01 00:01
CRDT- 1986/02/01 00:00
PHST- 1986/02/01 00:00 [pubmed]
PHST- 1986/02/01 00:01 [medline]
PHST- 1986/02/01 00:00 [entrez]
PST - ppublish
SO  - Arzneimittelforschung. 1986 Feb;36(2A):390-4.